Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Low density lipoprotein cholesterol: is lower better?

¹St Michael's Hospital, Toronto, Canada. leiter@smh.toronto.on.ca

The Canadian Journal of Cardiology

|February 2, 2000

Summary

Lowering low-density lipoprotein cholesterol (LDL-C) significantly reduces coronary events and mortality. Achieving lower LDL-C levels, often with statins, offers substantial cardiovascular benefits, especially for high-risk individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A systematic review and meta-analysis of randomized trials of substituting soymilk for cow's milk and intermediate cardiometabolic outcomes: understanding the impact of dairy alternatives in the transition to plant-based diets on cardiometabolic health.

BMC medicine·2024

Same author

Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials.

Diabetes & metabolism·2019

Same author

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

Diabetic medicine : a journal of the British Diabetic Association·2019

Same author

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.

Diabetic medicine : a journal of the British Diabetic Association·2017

Same author

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Diabetes & metabolism·2017

Area of Science:

Cardiology
Pharmacology
Preventive Medicine

Background:

Low-density lipoprotein cholesterol (LDL-C) is a key risk factor for cardiovascular disease.
Significant reductions in coronary events and mortality are linked to LDL-C lowering.
The lowest risk profiles are observed in individuals with the lowest LDL-C levels.

Purpose of the Study:

To review the impact of LDL-C reduction on cardiovascular outcomes.
To evaluate the efficacy of lipid-lowering drugs, primarily statins, in achieving LDL-C targets.
To assess the relationship between the degree of LDL-C reduction and clinical benefits.

Main Methods:

Review of major clinical trials involving statins and other lipid-lowering therapies.
Analysis of data correlating LDL-C levels with coronary events and mortality.
Examination of benefits across diverse patient populations (men, women, elderly, high-risk individuals).

Main Results:

LDL-C reduction is consistently associated with decreased coronary events and mortality in major trials.
Statins effectively lower LDL-C, leading to significant reductions in cardiovascular events.
Greatest clinical benefits are observed with the largest LDL-C reductions, with diminishing returns at very low levels.

Conclusions:

Achieving target LDL-C levels, often below 2.5 mM, is crucial for high-risk individuals to prevent coronary events.
Statins are primary agents for effective LDL-C reduction and cardiovascular risk management.
Ongoing research is vital to establish optimal future LDL-C treatment targets for maximum benefit.

Related Experiment Videos